The hMSC Standard In The Ivory Tower

By Jessica Snyder

Living cells must be commercially available as a predictable raw material for future breakthroughs in the cellular therapy community and the rapidly maturing field of regenerative medicine. Industrialized quality control establishes a reliable process between researcher, regulator, and clinician. In addition to safety and efficacy in experimental trials, cellular manufacturing must be cleared of bottlenecks to meet demand on a commercial scale.

We accepted the challenge and built a business to enable a system of high quality and scalable volumes (billions) of human mesenchymal stromal cells (hMSC), paired media systems, and Good Manufacturing Practice (GMP) bioprocess expertise. But, did it work?